Abstract

Objective: We have recently established a complex genetic basis for fibromuscular dysplasia (FMD), a common cause of renovascular hypertension (HTN). Here we aimed to replicate the association between the PHACTR1 locus and FMD in a Polish case control study, and assess the effect of this genetic locus on clinical features of patients. Design and method: Patients are part of the ARCADIA-POL study (75% women, mean age =45 ± 11yrs) with confirmed FMD in at least one vascular bed. All patients underwent detailed clinical evaluation including: ABPM, biochemical evaluation, duplex Doppler and whole-body angio-CT. Controls were randomly ascertained from the WOBASZ study, a population-based Polish cohort. Genotyping for rs9349379 was by direct sequencing. We used logistic regression and global effect estimation using METAL, Mann-Whitney test for continuous traits and Fischer exact test for categories. Results: We analysed 151 FMD patients and 298 controls, all with European ancestry. We confirmed the association between rs9349379 and FMD in the ARCADIA-POL case control study and found 56% increased risk for FMD risk per A allele (OR = 1.56; 95%CI = 1.14–2.13; P = 5.5 × 10–3). We now globally update the estimated effect of this risk variant on FMD through meta-analysis of 1,283 FMD cases and 4,193 controls, (OR = 1.40; 95%CI = 1.27–1.55; P = 1.8 × 10–11). Among the 151 Polish patients, we found equal distribution of rs9349379 genotypes in both sexes (P = 0.64), current (P = 0.27) or ex-smokers (P = 0.42) and multifocal and unifocal FMD sub-phenotypes (P = 0.33). Patients with AG/AA genotypes tend to be less likely to present multivessel FMD (19%vs48% in GG patients, P = 0.04). No differences were found between mean age of FMD (P = 0.70) of HTN (0.77) diagnosis. However, patients with AG/AA genotypes tend to have an average of 4.4 years more delay between HTN and FMD diagnosis (P = 0.04). Conclusions: We provide confirmatory association between PHACTR1 locus with FMD in this first genetic study in a Polish population and an updated global effect through the largest existing genetic meta-analysis for this disease. Further confirmation is required for the association we observed among the risk allele carriers with less arterial beds affected and in longer delay of FMD diagnosis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.